Cerevel Therapeutics Holdings, Inc.

Good morning. Welcome to Saville Therapeutics' third quarter 2021 financial results conference call. At this time, I'll participate and listen on the mode. Later, you will have the opportunity to ask a question during the Q&A portion of the call. Please note that this call may be recorded. I will now hand it to Matt Calistri, Vice President, Corporate Strategy and Investment Relations.

Thank you. Good morning, everyone. We appreciate you joining us for our third quarter 2021 results call. On today's call, you'll be hearing from Dr. Tony Coles, our chairperson and chief executive officer, Dr. Ray Sanchez, our chief medical officer, Dr. John Renger, our chief scientific officer, and Mark Bodenrater, our interim chief financial officer. Please refer to our press release from this morning, detailing our Q3 performance, as well as our updated corporate presentation, both of which are available on our website. I would like to remind you that we will be making forward-looking statements that reflect our current views related to our financial performance, future events, and industry and market conditions, as well as forward-looking statements including the potential attributes and benefits of our product candidates and the format and timing of our product development activities and clinical trials. We strongly encourage you to review the information that we file with the SEC regarding specific risks and uncertainties. I will now hand it over to Dr. Tony Coles, Chairperson and CEO of Cerevel, to provide an overview of our achievements and outlook.

Thanks, Matt, and good morning, everyone. Thank you for joining us today. Earlier this year, we announced top-line results from our Phase 1b trial of CBL231, our M4-selective positive allosteric modulator, or PAM, in schizophrenia. That compelling data represented our first major step toward realizing our aspiration of becoming the premier neuroscience company. In the early part of the third quarter, we secured $350 million in a follow-on offering and redeemed our outstanding public warrants. Now, we're well equipped with the people, the capital, and the momentum to execute on our programs and bring much-needed medicines to patients as rapidly as possible. Last month, we held a virtual R&D event where we discussed CBL871, a D1, D5 partial agonist in development for dementia-related apathy, and released additional data for CBL231. These are just two of the many programs in our broad portfolio, all of which leverage our deep understanding of neurocircuitry and receptor subtype selectivity to drive therapeutic benefit while minimizing side effects. Specifically, we are advancing CBL231 rapidly into phase two. We shared the broad outlines of our development program during our R&D event a few weeks ago, which Ray will review again in just a moment. And we'll provide additional details on the timing and design of that program by mid to late first quarter of next year. We also expect additional data readouts in the next few years across other programs in our pipeline. We anticipate two data readouts for DERIGABAT in 2022 with data from our phase one acute anxiety trial now expected by the end of the first quarter of 2022 and the readout from our phase two focal epilepsy trial in the second half of the year. Also in the second half of 2022, we expect a phase two readout of CVL871 in dementia-related apathy. And in 2023, of course, We expect data from our Phase III program for Tevapidon in both early and late-stage Parkinson's. In addition, we have a robust early-stage pipeline, including multiple programs in development for substance use disorder and major depressive disorder. We also have state-of-the-art laboratories and discovery capabilities at our brand-new Cambridge Crossing facility, where we intend to identify new neuroscience drug targets, including some with disease-modifying potential. With the depth of a pipeline that spans all stages of development, we're well-positioned to deliver a number of important catalysts in 2022, 2023, and beyond. Now, let me ask Dr. Ray Sanchez, our Chief Medical Officer, to provide the latest updates on our clinical development efforts. Ray?